icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 23-26 2021
Back grey_arrow_rt.gif
Persistent long-term risk of liver related complications in HCV patients after antiviral therapy - Data from the German Hepatitis C-Registry
  EASL 2021 June 23-26
Heiner Wedemeyer1,2, Peter Buggisch3, Stefan Mauss4, Albrecht Stoehr3, Hartwig Klinker5, Klaus HW Boeker6, Gerlinde Teuber7, Yvonne Serfert2, Markus Cornberg1,8, Heinz Hartmann2, Dietrich Huppe9, Christoph Sarrazin10,11, Karl-Georg Simon12, Stefan Zeuzem11, Thomas Berg13, German Hepatitis C-Registry7 1Hannover Medical School, Hannover, Germany; 2Leberstiftungs-GmbH Deutschland, Hannover, Germany; 3ifi-Institute for Interdisciplinary Medicine, Hamburg, Germany; 4Center for HIV and Hepatogastroenterology, Dusseldorf, Germany; 5University Hospital Wurzburg, Wurzburg, Germany; 6Center of Hepatology, Hannover, Germany; 7Practice PD Dr. med. G. Teuber, Frankfurt, Germany; 8Centre for Individualised Infection Medicine (CIIM), Hannover, Germany; 9Gastroenterologische Gemeinschaftspraxis Herne, Herne, Germany; 10St. Josefs-Hospital, Wiesbaden, Germany; 11Goethe University Hospital, Frankfurt, Germany; 12MVZ Dres. Eisenbach, Simon, Schwarz GbR, Leverkusen, Germany; 13University Hospital Leipzig, Leipzig, Germany


The overall incidence for de novo HCC was 0.6%/year. In patients with liver cirrhosis the annual HCC risk was 1.2% in the first two years after treatment and 0.8% from year 3-7. Liver cirrhosis and treatment experience were the only baseline parameters being associated with de novo HCC development with high significance (p<0.01; Table 1).